In JoVE (2)
Articles by Thomas D'huys in JoVE
קינטי מבוסס על-ידי קרינה פלואורסצנטית Ca2 + גיוס Assay לזהות את G-חלבון בשילוב קולטן אגוניסטים היריבים, מאפננים Allosteric Sandra Claes1, Thomas D'huys1, Anneleen Van Hout1, Dominique Schols1, Tom Van Loy1 1Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven וזמינותו הסלולר המתוארת נועד לצורך זיהוי הקולטן כימוקין CXC 4 (CXCR4)-סוכנים שמעצבת לעכב או לגרות, תחרותי או allosterically, תאיים Ca2 + שחרור שיזם CXCR4 הפעלה.
וזמינותו מבוססי Cytometry זרימה כדי לזהות תרכובות לשבש קשירה של ליגנד כימוקין שכותרתו Fluorescently CXC 12 לקולטן כימוקין CXC 4 Geert Schoofs1, Anneleen Van Hout1, Thomas D'huys1, Dominique Schols1, Tom Van Loy1 1Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven זרם איגוד הסלולר מבוססי cytometry assay מתואר זה משמש בעיקר ככלי מיון כדי לזהות תרכובות המעכבות את הכריכה של ליגנד כימוקין CXC fluorescently שכותרתו 12 (CXCL12) לקולטן כימוקין CXC 4 (CXCR4).
Other articles by Thomas D'huys on PubMed
Aspartate-Based CXCR4 Chemokine Receptor Binding of Cross-Bridged Tetraazamacrocyclic Copper(II) and Zinc(II) Complexes Chemistry (Weinheim an Der Bergstrasse, Germany). | Pubmed ID: 27458983 The CXCR4 chemokine receptor is implicated in a number of diseases including HIV infection and cancer development and metastasis. Previous studies have demonstrated that configurationally restricted bis-tetraazamacrocyclic metal complexes are high-affinity CXCR4 antagonists. Here, we present the synthesis of Cu(2+) and Zn(2+) acetate complexes of six cross-bridged tetraazamacrocycles to mimic their coordination interaction with the aspartate side chains known to bind them to CXCR4. X-ray crystal structures for three new Cu(2+) acetate complexes and two new Zn(2+) acetate complexes demonstrate metal-ion-dependent differences in the mode of binding the acetate ligand concomitantly with the requisite cis-V-configured cross-bridged tetraazamacrocyle. Concurrent density functional theory molecular modelling studies produced an energetic rationale for the unexpected [Zn(OAc)(H2 O)](+) coordination motif present in all of the Zn(2+) cross-bridged tetraazamacrocycle crystal structures, which differs from the chelating acetate [Zn(OAc)](+) structures of known unbridged and side-bridged tetraazamacrocyclic Zn(2+) -containing CXCR4 antagonists.
Comparison of Cell-based Assays for the Identification and Evaluation of Competitive CXCR4 Inhibitors PloS One. | Pubmed ID: 28410420 The chemokine receptor CXCR4 is activated by its unique chemokine ligand CXCL12 and regulates many physiological and developmental processes such as hematopoietic cell trafficking. CXCR4 is also one of the main co-receptors for human immunodeficiency virus (HIV) entry. Dysfunction of the CXCL12/CXCR4 axis contributes to several human pathologies, including cancer and inflammatory diseases. Consequently, inhibition of CXCR4 activation is recognized as an attractive target for therapeutic intervention. In this regard, numerous agents modifying CXCR4 activity have been evaluated in in vitro experimental studies and pre-clinical models. Here, we evaluated a CXCL12 competition binding assay for its potential as a valuable initial screen for functional and competitive CXCR4 inhibitors. In total, 11 structurally diverse compounds were included in a side-by-side comparison of in vitro CXCR4 cell-based assays, such as CXCL12 competition binding, CXCL12-induced calcium signaling, CXCR4 internalization, CXCL12-guided cell migration and CXCR4-specific HIV-1 replication experiments. Our data indicated that agents that inhibit CXCL12 binding, i.e. the anti-CXCR4 peptide analogs T22, T140 and TC14012 and the small molecule antagonists AMD3100, AMD3465, AMD11070 and IT1t showed inhibitory activity with consistent relative potencies in all further applied CXCR4-related assays. Accordingly, agents exerting no or very weak receptor binding (i.e., CTCE-9908, WZ811, Me6TREN and gambogic acid) showed no or very poor anti-CXCR4 inhibitory activity. Thus, CXCL12 competition binding studies were proven to be highly valuable as an initial screening assay and indicative for the pharmacological and functional profile of competitive CXCR4 antagonists, which will help the design of new potent CXCR4 inhibitors.